Results 21 to 30 of about 41,944 (264)

PARP inhibition: a promising therapeutic target in ovarian cancer [PDF]

, 2015
Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery.
Abdul Halim, T, BENEDETTI PANICI, PIERLUIGI, CASORELLI, ASSUNTA, DI DONATO, VIOLANTE, DOMENICI, LAVINIA, GASPARRI, MARIALUISA, IMPERIALE, LUDOVICA, MARCHETTI, CLAUDIA, MONTI, Marco, MUSELLA, ANGELA, MUZII, LUDOVICO, PALAIA, INNOCENZA, PECORINI, Francesco, RUSCITO, ILARY, SALERNO, LAURA   +14 more
core   +1 more source

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

New England Journal of Medicine, 2018
BACKGROUND Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment with surgery and platinum‐based chemotherapy.
K. Moore, N. Colombo, G. Scambia, Byoung-Gie Kim, A. Oaknin, M. Friedlander, A. Lisyanskaya, A. Floquet, A. Leary, G. Sonke, C. Gourley, Susana Banerjee, A. Oza, A. González-Martín, C. Aghajanian, W. Bradley, C. Mathews, Joyce F. Liu, E. Lowe, R. Bloomfield, P. DiSilvestro   +20 more
semanticscholar   +1 more source

Defective DNA repair mechanisms in prostate cancer: impact of olaparib [PDF]

, 2017
The field of prostate oncology has continued to change dramatically. It has truly become a field that is intensely linked to molecular genetic alterations, especially DNA-repair defects.
De Felice, Francesca, Marampon, Francesco, Marchetti, Claudia, Musella, Angela, Tombolini, Vincenzo   +4 more
core   +2 more sources

Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer

Translational Oncology, 2019
Castration-resistant prostate cancer remains as an incurable disease. Exploiting DNA damage repair defects via inhibition of poly (ADP-ribose) polymerase (PARP) is becoming an attractive therapeutic option.
Alan P Lombard, Chengfei Liu, Cameron M Armstrong, Leandro S D'Abronzo, Wei Lou, Hongwu Chen, Marc Dall'Era, Paramita M Ghosh, Christopher P Evans, Allen C Gao   +9 more
doaj   +1 more source

The PARP-1 inhibitor Olaparib causes retention of γ-H2AX foci in BRCA1 heterozygote cells following exposure to gamma radiation [PDF]

, 2013
This article is made available through the Brunel Open Access Publishing Fund. Copyright © 2013 Emma C. Bourton et al. This is an open access article distributed under the Creative Commons Attribution Li-cense, which permits unrestricted use ...
Adam Zahir, S, Bourton, EC, Harvey, AJ, Parris, CN, Plowman, PN   +4 more
core   +1 more source

Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis

Journal of Obstetrics and Gynaecology, 2023
This study aimed to evaluate the efficacy and safety of olaparib for the treatment of advanced ovarian cancer. All studies that assessed the efficacy and safety of olaparib in advanced ovarian cancer were searched in PubMed, Embase, and Web of Science ...
Yuanyuan Yang, Xiaoyun Yang, Huaifang Li, Xiaowen Tong, Xinxian Zhu   +4 more
doaj   +1 more source

The suppression of DNA repair induced by PARP-1 inhibitors rucaparib and olaparib in combination with the radiopharmaceutical 131I-MIBG in noradrenaline transporter-expressing xenograft tumors [PDF]

, 2018
No abstract ...
Gaze, Mark N., Mairs, Robert J., Nile, Donna L., Nixon, Colin, Rae, Colin   +4 more
core   +1 more source

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

New England Journal of Medicine, 2019
BACKGROUND Patients with a germline BRCA1 or BRCA2 mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population ...
T. Golan, P. Hammel, M. Reni, E. Van Cutsem, T. Macarulla, M. Hall, Joon-Oh Park, D. Hochhauser, D. Arnold, D. Oh, A. Reinacher-Schick, G. Tortora, H. Algül, E. O’Reilly, D. McGuinness, K. Cui, K. Schlienger, G. Locker, H. Kindler   +18 more
semanticscholar   +1 more source

Nanoengineered Gallium Ion Incorporated Formulation for Safe and Efficient Reversal of PARP Inhibition and Platinum Resistance in Ovarian Cancer

Research, 2023
Platinum-based chemotherapy remains the main systemic treatment of ovarian cancer (OC). However, the inevitable development of platinum and poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) resistance is associated with poor outcomes ...
Yangyang Li, Yixuan Cen, Mengyan Tu, Zhenzhen Xiang, Sangsang Tang, Weiguo Lu, Hongbo Zhang, Junfen Xu   +7 more
doaj   +1 more source

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment [PDF]

, 2016
Background: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience relapses with a median ...
Caruso, Davide, Papa, Anselmo, Strudel, Martina, Tomao, Federica, Tomao, Silverio   +4 more
core   +2 more sources